Thursday, 5 Nov 2009 | Source: CNBC staff and wire reports
New York City health officials scrambled to explain themselves Thursday following outraged media reports about bankers who got scarce H1N1 flu vaccines through their employers
Wednesday, 4 Nov 2009 | Source: The Associated Press
The new Merck becomes the world's second-biggest drugmaker overnight, and it's boasting a fat wallet to fund future deals.
A new study says doctors should be especially vigilant about people who are over 50 with flu symptoms because they appear to have a higher risk of death from H1N1.
The director of the FDA's division of antiviral products is urging caution in the use of a new flu drug that just won special permission to fight H1N1.
Monday, 2 Nov 2009 | Source: Reuters
Dendreon has completed its U.S. regulatory submission for its closely watched experimental prostate cancer vaccine, the company said Monday, sending its shares up 5 percent.
A large study being published in a major medical journal says certain kidney disease patients who get the drug Aranesp to treat anemia-related fatigue may be at greater risk of having a stroke.
Tuesday, 27 Oct 2009 | Source: Reuters
GlaxoSmithKline has yet to get U.S. government approval for its swine flu vaccine, the company said Tuesday, while Novartis said it was still struggling to make vaccines.
Saturday, 24 Oct 2009 | Source: Reuters
U.S. President Barack Obama has declared 2009 H1N1 swine flu a national emergency, the White House said Saturday.
The Food and Drug Administration has given what's called Emergency Use Authorization for a new H1N1 flu drug.
Friday, 23 Oct 2009 | Source: Reuters
Healthcare companies are reaping the benefits of a global swine flu pandemic, brightening what might otherwise have been a dismal third quarter and bringing new focus on the market for vaccines.
Friday, 23 Oct 2009 | Source: Reuters
U.S. drugmaker Merck & Co's $41.1 billion takeover of smaller rival Schering-Plough won approval from European Union antitrust regulators Friday.
A new study shows that a diabetes treatment awaiting FDA approval may also work as a weightloss drug.
Tuesday, 20 Oct 2009 | Source: CNBC.com
Pfizer's acquisition of Wyeth will add to the pharmaceutical giant's diversity, which over time will help boost the company's stock, CEO Jeff Kindler told CNBC Tuesday.
Friday, 16 Oct 2009 | Source: Reuters
A U.S. court on Friday imposed $1.3 billion in criminal penalties on Pfizer
Thursday, 15 Oct 2009 | Source: Reuters
Pfizer completed its roughly $67 billion acquisition of U.S. rival Wyeth on Thursday, as the world's largest drugmaker gets even bigger.
Posts |
TOPIC : Pharmaceuticals
6 Nov 2009
Stacy and Clinton definitely had nothing to do with it, but Sanofi-Pasteur (the vaccines division of Sanofi-Aventis) greets visitors with a "What Not To Wear" brochure... Read More
4 Nov 2009
I am not a Trekkie... Read More
3 Nov 2009
Pfizer, or one of its ad agencies, is apparently putting out a casting call for a new Lipitor pitchman.... Read More
2 Nov 2009
Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma... Read More
30 Oct 2009
I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill... Read More
VIDEO | TOPIC : Pharmaceuticals
Flu vaccines were once a business that many drug companies avoided, but that segment of the pharma industry is now firml...
A pharma insider gives an outlook for the sector, with Brian Markison, King Pharmaceuticals CEO.
The reflation trade is likely to continue in the near term, believes Lim Say Boon, chief investment strategist from Stan...
Cramer takes a look at some companies that are making major strides in treating cancer.
More Videos
About CNBC | Site Map | Privacy Policy | Terms of Service | Video Reprints | Advertise | Help | Contact
Partners: AOL Money | BloggingStocks.com
Partners: AOL Money | BloggingStocks.com
Data is a real-time snapshot *Data is delayed at least 15 minutesGlobal Business and Financial News, Stock Quotes, and Market Data and Analysis
© 2009 CNBC, Inc. All Rights Reserved.
A Division of NBC Universal
